Xeris Biopharma Q3 2026 Earnings Date & Estimates

Xeris Biopharma (NASDAQ:XERS), Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome. The company also markets Ogluo, a glucagon autoinjector, in certain markets. Its products are primarily marketed in the United States, with selected international availability supported through commercial partners and regional arrangements.

The company was established as Xeris Pharmaceuticals and became a publicly traded company in 2018. In 2021, Xeris completed a combination with Strongbridge Biopharma, expanding its portfolio and adding therapies focused on rare endocrine diseases. In addition to its commercial products, Xeris continues to develop medicines and drug-delivery applications based on its proprietary formulation platforms.